OBJECTIVES: Aim of this study was to compare real-world treatment outcomes of dapagliflozin and basal supported oral therapy (BOT) among therapy in patients with type 2 diabetes in Germany. METHODS: Patients from 983 primary care practices who started dapagliflozin therapy or BOT between 01/12/2012 and 31/07/2015 (index date) were selected in the IMS Disease Analyzer database. Changes from baseline in HbA1c and weight were evaluated in the time periods of 3-9 months. Dapagliflozin patients who additionally received insulin prescriptions and BOT patients who received SGLT-2 prescriptions were excluded from the analysis. Finally, 766 dapagliflozin patients were matched (1:1) to BOT patients by propensity scores based on age, sex, health insurance coverage, diabetologist care, oral antihyperglycemic therapy (metformin, sulfonylurea, DPP-4 inhibitors), baseline HbA1c/BMI value and therapy duration till the last HbA1c/weight documentation after index date. RESULTS: